Lundbeck LLC
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$46.4M
Doctors Paid
66,563
Transactions
474,600
2024 Total
$4.1M
Payment Breakdown by Category
Royalty/License$19.3M (41.6%)
Food & Beverage$8.5M (18.4%)
Research$6.7M (14.4%)
Consulting$2.0M (4.3%)
Travel$1.0M (2.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Royalty or License | $19.3M | 33 | 41.6% |
| Food and Beverage | $8.5M | 462,340 | 18.4% |
| Honoraria | $7.7M | 4,103 | 16.6% |
| Unspecified | $6.7M | 151 | 14.4% |
| Consulting Fee | $2.0M | 2,164 | 4.3% |
| Travel and Lodging | $1.0M | 4,359 | 2.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $658,653 | 14 | 1.4% |
| Grant | $367,200 | 13 | 0.8% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $124,500 | 3 | 0.3% |
| Charitable Contribution | $52,300 | 32 | 0.1% |
| Education | $6,272 | 1,388 | 0.0% |
Payments by Type
General
$39.8M
474,449 transactions
Research
$6.7M
151 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Preventing Epilepsy using Vigabatrin in Infants with TB Complex (PREVENT Trial), a randomized, double-blind, placebo controlled seizure prevention clinical trial for infants with TSC | $3.5M | 0 | 1 |
| Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension RESTORE | $1.0M | 17 | 102 |
| Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia Anew | $1.0M | 0 | 1 |
| N/A | $168,633 | 0 | 5 |
| Effects of L-Dihydoxyphenyserine (L-DOPS, Northera) a central and peripheral norepinephrine agent on locomotion, postural stability (balance), and Fall Reduction in PD | $136,741 | 0 | 1 |
| Evaluation of add-on treatment of adults with refractory localization related epilepsy with clobazam A pilot study | $92,600 | 0 | 1 |
| Technology-Based Objective Measures for Gait and Postural Assessment in Parkinson Disease Patients with Orthostatic Hypotension Feasibility and Effect-Size Finding Study | $77,828 | 0 | 1 |
| Northera Improves Postural Tachycardia Syndrome POTS and Postural Vasovagal Syncope VVS | $77,828 | 0 | 1 |
| Evaluation of Brain Perfusion and Oxygenation in PD patients with Neurogenic Orthostatic Hypotension: 4 Week Comparison of droxidopa versus Placebo | $76,527 | 0 | 1 |
| Northera Improves Postural Tachycardia Syndrome (POTS) and Postural Vasovagal Syncope (VVS) | $68,215 | 0 | 2 |
| Evaluate Efficacy & Safety of Eptinezumab Administered Intravenously in Subjects Experiencing Acute Attack of Migraine RELIEF | $51,500 | 0 | 5 |
| Clobazam Adjunctive Treatment of Adults With Refractory Focal Epilepsy | $46,000 | 0 | 1 |
| A Retrospective Study Safety and efficacy of Clobazam in Children with Seizures Less Than Two Years of Age | $41,210 | 0 | 2 |
| A Randomized, Double-Blind, Placebo-Controlled Study of Droxidopa for Fatigue in Parkinson's Disease | $40,965 | 0 | 1 |
| Safety and efficacy of droxidopa for fatigue in patients with Parkinsonism | $37,637 | 0 | 1 |
| Clinical Diagnosis of Neurogenic Orthostatic Hypotension | $35,122 | 0 | 1 |
| Treatment of Anxiety Comorbid with Epilepsy | $28,760 | 0 | 1 |
| An Open Label Trial of ALD403 Eptinezumab in Chronic Migraine PREVAIL | $24,274 | 0 | 5 |
| Evaluation of ALD403 Eptinezumab in the Prevention of Chronic Migraine PROMISE 2 | $23,657 | 0 | 2 |
| Norepinephrine-targeted therapy for action control in parkinson disease | $15,604 | 0 | 1 |
| Technology-Based Objective Measures for Gait and Postural Assessment in Parkinson Disease Patients with Orthostatic Hypotension: Feasibility and Effect-Size Finding Study | $14,904 | 0 | 1 |
| Effects of Clobazam on sleep and daytime function in patients with epilepsy | $13,057 | 0 | 1 |
| Epilepsy Birth Control Registry - Full Prospective Study | $12,955 | 0 | 1 |
| Effects of Droxidopa When Measuring Gait Speed, Kyphosis, and Functional Reach in Parkinson's Disease (droxidopa) | $11,975 | 0 | 1 |
| Assessing Impulsivity and Suicidality in Xenazine | $7,784 | 0 | 1 |
| Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine (PROMISE 2) | $7,587 | 0 | 2 |
| Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension (RESTORE) | $7,000 | 0 | 1 |
| Brain Perfusion & Oxygenation in Parkinsons Disease With NOH | $5,919 | 0 | 1 |
| Norepinephrine-targeted Therapy for Action Control in Parkinson Disease | $3,057 | 0 | 1 |
| Electrophysiological and behavioral characterizations of droxidopa as a potential drug for ADHD | $2,000 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 4
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Amy Tees, Np-C, NP-C | Family | Tucson, AZ | $39,261 | $0 |
| Dr. Megan Donnelly, D.o, D.O | Neurology | Charlotte, NC | $38,715 | $0 |
| Thomas Ahern, M.d, M.D | Cardiovascular Disease | La Jolla, CA | $38,670 | $0 |
| Dr. Stephanie Delgaudio-Riemann, M.d, M.D | Specialist | Woodstock, GA | $38,404 | $0 |
| Dr. Shannon Standridge, D.o, D.O | Neurology with Special Qualifications in Child Neurology | Cincinnati, OH | $37,776 | $0 |
| Reversa Joseph, Md, MD | Neurology | Columbus, OH | $37,709 | $0 |
| Dr. Hossein Ansari, M.d, M.D | Neurology | San Diego, CA | $37,681 | $0 |
| Dr. Eric Baron, D.o,, D.O, | Neurology | Cleveland, OH | $36,978 | $0 |
| Christopher Rhyne, M.d, M.D | Family Medicine | Louisville, KY | $36,967 | $0 |
| John Rothrock, Md, MD | Neurology | Fairfax, VA | $36,455 | $0 |
| Kavita Kalidas, M.d, M.D | Neurology | Lutz, FL | $36,341 | $0 |
| Dr. John Hemphill, M.d, M.D | Neurology with Special Qualifications in Child Neurology | Savannah, GA | $36,311 | $0 |
| Anthony Simchak, Md, MD | Neurology | Lafayette, IN | $36,080 | $0 |
| Dr. Ibrahim Elgabry, M.d, M.D | Internal Medicine | Woonsocket, RI | $35,874 | $0 |
| Dr. Duarte Machado, M.d, M.D | Student in an Organized Health Care Education/Training Program | Cheshire, CT | $35,336 | $0 |
| David King-Stephens, M.d, M.D | Neurology | Orange, CA | $35,321 | $0 |
| Fawad Khan, Md, M.b.b.s, MD, M.B.B.S | Neurology | New Orleans, LA | $35,258 | $0 |
| Amit Verma, Md, MD | Neurology | Houston, TX | $34,939 | $0 |
| Steve Chung, M.d, M.D | Neurology | Phoenix, AZ | $34,757 | $0 |
| Dr. Jeffrey Kaplan, M.d, M.D | Neurology | Lenexa, KS | $34,736 | $0 |
| Eric Eross, Do, DO | Specialist | Phoenix, AZ | $34,217 | $0 |
| Jesus Pina-Garza, Md, MD | Neurology | Nashville, TN | $33,781 | $0 |
| Nisha Chhabria, Md, MD | Neurology | West Palm Beach, FL | $33,694 | $0 |
| Dr. Jason Eckel, M.d, M.D | Nephrology | Cary, NC | $33,474 | $0 |
| Mr. Jack Florin, Md, MD | Neurology | Fullerton, CA | $32,750 | $0 |
About Lundbeck LLC
Lundbeck LLC has made $46.4M in payments to 66,563 healthcare providers, recorded across 474,600 transactions in the CMS Open Payments database. In 2024, the company paid $4.1M. The top product by payment volume is SABRIL ($22.8M).
Payments were distributed across 306 medical specialties. The top specialty by payment amount is Neurology with Special Qualifications in Child Neurology ($10.2M to 369 doctors).
Payment categories include: Food & Beverage ($8.5M), Consulting ($2.0M), Research ($6.7M), Travel & Lodging ($1.0M), Royalties ($19.3M).
Lundbeck LLC is associated with 5 products in the CMS Open Payments database, including SABRIL, NORTHERA, and ONFI.